Edaravone effects on the expression levels of collagen type I and IV after spinal cord injury in rats

doi:10.3969/j.issn.2095-4344.0142

Abstract

Abstract:

BACKGROUND: Edaravone, an effective free radical scavenger, has been reported to significantly improve the rehabilitation of limb locomotion after spinal cord injury (SCI), but the underlying mechanism remains unclear.
OBJECTIVE: To explore the mechanism underlying edaravone promoting the recovery of limb locomotion in rats with SCI by observing the Basso, Beattie, Bresnahan scores and expression levels of collagen type I and IV.
METHODS: Thirty-six rats were randomly allocated into three groups (n=12 per group): sham group (laminectomy plus intraperitoneal injection of normal saline), model group (SCI model by NYU impactor plus intraperitoneal injection of normal saline), and edaravone group (SCI model by NYU impactor plus intraperitoneal injection of edaravone). All rats were given the administration at the 1st day post-SCI for consecutive 7 days. The Basso, Beattie, Bresnahan scores were tested at 1, 3, 5 and 7 days post treatment. On day 7, all rats were sacrificed to remove the spinal cord, and the morphology of neurons in the spinal cord were observed by Nissl staining; the expression levels of collagen type I and IV were detected by immunohistochemistry and western blot assays.
RESULTS AND CONCLUSION: Compared with the model group, the Basso, Beattie, Bresnahan scores in the edaravone group were significantly increased at day 5 post treatment (P < 0.05). Nissl staining showed a clear boundary between grey matter and white matter, and a large nucleolus in the neurocytoplasm in the sham group; there was a complete structure of neurons, slight cellular swelling and small hematoma area in the edaravone group; many and large cavitations and swollen nucleus were found in the neurons, even without nucleolus. Immunohistochemistry and western blot assay results showed that the expression levels of collagen type I and IV in the edaravone group were significantly higher than those in the model group (P < 0.05). These results indicate that edaravone can promote the recovery of limb locomotion of rats with SCI, probably via up-regulating the expression levels of collagen type I and IV.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Spinal Cord Injuries, Models, Animal, Collagen Type I, Tissue Engineering

CLC Number:

R318

Li Ren-bin, Yu Guang-shu, Lin Yan-bin, Zhou Jia-feng, Huang Yi-qi, Zheng Wei. Edaravone effects on the expression levels of collagen type I and IV after spinal cord injury in rats[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(8): 1235-1240.

Figures/Tables 4

References

[1] Wenta C, Lin HC, Lam C, et al.Epidemiology of traumatic spinal cord injury: comparisons between developed and developing countries .Asia Pac J Public Health.2010;22(1): 9-18.

[2] 刘明永,赵建华,王爱民.脊髓损伤的细胞疗法进展[J].创伤外科杂志,2010,12(2):186-189.

[3] 杨成林,查雪峰.中西医结合治疗急性脊椎损伤的临床研究[J].中华中医药学刊, 2015,12: 3043-3046.

[4] 曾智谋,张寿,刘亦恒.脊髓损伤的病理生理及治疗进展[J].海南医学, 2013, 24(14): 2105-2108.

[5] Ren HZ, Zhang XS, Wang LX. Effect of coronary revascularization on serum collagen biomarkers and left ventricular remodeling in patients with acute myocardial infarction.Heart Lung.2012; 41(4):344-349.

[6] Hsu JYC, Mckeon R, Goussev S, et al. Matrix Metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord iInjury.J Neurosci. 2006;26(39):9841-9850.

[7] Mao M, Alavi MV, Cassandre LD, et al. Type IV collagens and basement membrane diseases: cell biology and pathogenic mechanisms. Curr Top Membr.2015;76:61-116.

[8] 郭文荣,李兴.糖尿病肾病与ADPN、TGF-β1、Collagen IV、ICAM-1关系的研究进展[J].医学研究杂志,2015,44(6):170-173.

[9] Anik I, Kokturk S, Genc H, et al. Immunohistochemical analysis of TIMP-2 and collagen types I and IV in experimental spinal cord ischemia-reperfusion injury in rats.J Spinal Cord Med. 2011;34(3):257-264.

[10] ]Tanaka M. Pharmacological and clinical prof'de of the free radical scavengeredaravone as a neuroprotective agent. Nippon Yakurigaku Zasshi. 2002;119(5):301-308.

[11] Yasuoka N, Nakajima W. Ishida A Neuroprotection of edaravone on hypoxic-ischemic brain injury in neonatal rats. Brain Res Dev Brain Res.2004;151(1-2):129-139.

[12] Takahashi G, Sakurai M, Abe K, et al. MCI-186 reduces oxidative cellular damage and increases DNA repair function in the rabbit spinal cord after transient ischemia. Ann Thorac Surg. 2004;78(2):602-607．

[13] Qi W, Niu J, Qin Q, et al. Glycated albumin triggers fibrosis and apoptosis via an NADPH oxidase/Nox4-MAPK pathway-dependent mechanism in renal proximal tubular cells.Endocrinology.2015;40(5):74-83.

[14] GorinY,BlockK,HernandezJ,et al. Nox4 NAD(P)H oxidase mediateshypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem. 2005;280(47):3616-3626.

[15] Sedeek M, Callera G,Montezano A, et al. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney-implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 2010;299(6): 1348-1358.

[16] Chen WF, Chen CH, Chen NF, et al. Neuroprotectiveeffects of direct intrathecaladministration of granulocyte colony-stimulatingfactor inrats with spinal cord injury. CNS Drugs. 2015;21(9):698-707.

[17] Xiong Y, Rabchevsky AG, Hall ED. Role of peroxynitrite in secondary oxidative damage after spinal cord injury.J Neurochem. 2007;100(3):639-649.

[18] Bareyre F M. Neuronal repair and replacement in spinal cord injury. J Neurol Sci. 2008;265(1):63-72.

[19] Nigam S, Schewe T. Phospholipase A(2)s and lipid peroxidation.BiochimBiophysActa. 2000;1488(1):167-181.

[20] 卢育南,许逸洋,曾奕,等.二甲亚砜对脊髓损伤的抗自由基保护作用[J].解剖学研究, 2012, 34(1):16-20.

[21] Tator CH, Koyanagi I. Vascular mechanisms in the pathophysiology of human spinal cord injury. Neurosurg. 1997;86(3): 483-492.

[22] Akdemir H, Pasaoglu A. Histopathology of experimental spinal cord truma. Comparison of treatment with TRH, naloxone, and dexamethasone. Res ExpMed(Berl). 1992; 192(3):177-183.

[23] Bullock R, Fujisawa H. The role of gultamata antagonists for the treatment of CNS injury. Neurotrauma.1992;9(Suppl 2): 443-446.

[24] Pernet V, Schwab ME. The role of Nogo-A in axonal plasticity,regrowth and repair . Cell Tissue Res.2012;349(1): 97-104.

[25] Yuan YM, He C.The glial scar in spinal cord injury and repair.Neurosci Bull.2013;29(4):421-435.

[26] 何创. Caveolin-1 对内毒素性肺损伤TGF-β1/Smads信号通路的调控[D].广州中医药大学,2012.

[27] Masahiko J, Tanaka B.Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotectiveagent. Bull Med Libr Assoc. 2002;119(5): 301-308.

[28] Hamaishi M, Orihashi K, IsakaM, et al. Low-dose edaravoneinjection into the clamped aorta prevents ischemic spinal cord injury.Ann Vasc Surg.2009;23(1):128-135.

[29] 陈继革,吴华.依达拉奉促进大鼠脊髓损伤神经功能恢复作用研究[J].医药导报, 2007, 26(2):147-148.

[30] Sweeney SM, Dilullo G, Slater SJ, et al. Angiogenesis in collagen I requires alpha2beta1 ligation of a GFP*GER sequence and possibly p38 MAPK activation and focal adhesion disassembly.J Biol Chem. 2003;278(33): 30516-30524.

[31] Verrecchia F, Mauviel A. TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Mol Cell Biol. 2004;16(8):873-880.